|Articles|October 15, 2002
- BioPharm International-10-01-2002
- Volume 15
- Issue 10
Biotech Will Recover!
Author(s)G. Steven Burrill
by G. Steven Burrill, Burrill & Company Beleagured by bad news since the start of the year, biotech is barely registering a pulse on Wall Street . . . but it's hardly time to write the industry's obituary.
Advertisement
Articles in this issue
almost 23 years ago
FDA Launches Major CGMP Reviewalmost 23 years ago
Process Validation: How Much to Do and When to Do Italmost 23 years ago
GMPs and Pharmaceutical Labelingalmost 23 years ago
Revolutionizing Biologics RegulationNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
